These key findings suggest that targeting STAT1 and STAT3 signaling could be a therapeutic target for treating the inflammatory phenotype associated with senescence in obesity-driven T2DM. The gene discussed is STAT1; the disease is obesity due to melanocortin 4 receptor deficiency.